34 Facts About Brett Giroir

Brett Giroir was formerly the US assistant secretary for health, a four-star admiral in the US Public Health Service Commissioned Corps and an acting Food and Drug Administration commissioner.

Brett Giroir starting in 2016 served as president and CEO of ViraCyte, LLC, a clinical-stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for severe infections.

Brett Giroir served as a senior fellow at the Texas Medical Center Health Policy Institute and strategic advisor for the Texas Medical Center Innovation Institute.

Brett Giroir was a member of the Texas Task Force for Infectious Disease Preparedness and Response, and an adjunct professor of pediatrics at the Baylor College of Medicine in Houston.

Brett Giroir served as the Acting Commissioner of Food and Drugs in November and December 2019, while Stephen Hahn's nomination was pending in the Senate.

Brett Giroir graduated from all-male Catholic Jesuit High School in New Orleans, Louisiana, where he was served as a drill team commander in the US Marine Corps JROTC.

Brett Giroir was the first to attend college in his family.

Brett Giroir received his post-doctoral training at the Howard Hughes Medical Institute in Dallas, from 1991 to 1993.

Brett Giroir was the inaugural holder of the Associates First Capital Corporation Distinguished Chair in Pediatrics, and the Kathryne and Gene Bishop Distinguished Chair in Pediatric Care.

In 2000, Brett Giroir was named the associate dean for Clinical Affairs at UTSW, while taking on the role as the inaugural chief medical officer at Children's Medical Center Dallas.

Brett Giroir's research focused on severe life-threatening infectious diseases, including meningococcal disease.

Brett Giroir's research was featured on a PBS NOVA entitled "Killer Disease on Campus" which originally aired in 2002.

Brett Giroir has published over 85 academic articles, chapters, and books on a variety of topics including host-pathogen interactions and novel therapies for life-threatening infectious diseases.

Brett Giroir co-chaired or participated in studies related to biological weapons decontamination and universal medial countermeasures to biological threats during his appointment with the DSRC.

In 2004, Brett Giroir accepted a full-time position at DARPA as deputy director of the Defense Sciences Office, and then as its director from 2007 to 2008.

Brett Giroir was selected as a member of the Defense Sciences Study Group, a two-year program to develop emerging leaders in science and technology.

Brett Giroir was a member of the external advisory board, NASA National Center for Space Biological Technologies, and the chair on the Chemical and Biological Defense Panel for the Threat Reduction Advisory Committee.

Brett Giroir testified to the House Committee on Veterans Affairs the following month and communicated priorities for VA reform.

Brett Giroir was told on 1 June 2015, that he had 30 minutes to resign or he would be fired.

Brett Giroir chose to resign, after eight years of work on several vaccine projects.

Brett Giroir was renominated on 8 January 2018, and confirmed via voice vote on 7 February 2018.

Brett Giroir received his commission and four-star rank in the commissioned corps, a week after he assumed the office of assistant secretary on 15 February 2018.

Brett Giroir was appointed by the secretary to the additional role as mental health senior adviser on 29 March 2018.

Admiral Brett Giroir stated he had not asked the companies to explain their dramatic price increases, but promised he would 'get back to [me] on whether [he] could write a letter.

In November 2018, Brett Giroir wrote a letter in which he said that the agency was seeking to end the use of fetal tissue in taxpayer-funded biomedical research involving developing vaccines and researching the Zika virus, and treatments for Alzheimer's disease and Parkinson's, if it can find "adequate alternatives", and said the HHS was "pro-life and pro-science".

On 1 November 2019, HHS Secretary Alex Azar announced that Brett Giroir would serve as Acting Commissioner of Food and Drugs until Stephen Hahn, whose nomination for the same position was announced on the same day, was confirmed by the US Senate.

On 15 November 2018, President Trump nominated Brett Giroir to serve the additional role of representative of the United States on the executive board of the World Health Organization.

Brett Giroir was renominated on January 16,2019, but that nomination was returned to the president on 3 January 2020, without action.

Brett Giroir was renominated for a third time on 18 March 2020.

Brett Giroir was finally confirmed by the Senate in a voice vote on 7 May 2020.

Brett Giroir served on the executive board, for the remainder of the current three-year term cycle, which expired in January 2021.

Brett Giroir resigned from his government positions on 19 January 2021, as expected from all appointed government leadership, in order to facilitate a smooth transition to the new Biden administration.

Brett Giroir appeared before the House Armed Services Committee Subcommittee on Intelligence, Emerging Threats and Capabilities hearing on Biodefense: Worldwide Threats and Countermeasure Efforts for the Department of Defense in October 2013.

Brett Giroir is the recipient of the following awards and decorations:.